Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 225

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 225
---
 to and inhibit the complement protein C5, preventing the cleavage of C5 into C5a and C5b and significantly reducing membrane attack complex (MAC) formation.

The recommended dosage of Izervay is 2 mg (equivalent to 0.1 mL of a 20 mg/mL solution), administered via intravitreal injection into each affected eye monthly for up to 12 months. Izervay is anticipated to be available in the US market very soon, and its cost is projected to be $2,100 per vial (that is $2,100 per injection).

14 https://xtalks.com/apellis-syfovre-approved-as-first-treatment-for-geographic-atrophy-despite-uncertain-clinical-benefit-3394/

15 https://xtalks.com/izervay-becomes-second-fda-approved-drug-for-geographic-atrophy-3500/

| Moore Financial Consulting |

| Telomir Pharmaceuticals, Inc.Valuation | November 2025Page 23 of 24 |

Following are our assumptions regarding the list price of an annual treatment for AMD, both early and late stages:

A Vial is for one shot in one eye. The recommended treatment for late-stage AMD (GA) is 6 shots (per eye) a year. The treatment is for lifetime ($ 25,800 annual treatment cost). For early-stage AMD there is no recommended treatment of the sort therefor we have assumed the following: 2 shot per year in only 1 eye (total annual treatment costs of $ 4,300).

Breast Cancer

We assumed that the Breast cancer drug under development will be an Adjuvant (after surgery) or Neoadjuvant (before surgery) treatment. We didn’t find any of these therapies for early stages of breast cancer that had only a branded therapy available. Usually, anthracyclines (like doxorubicin or epirubicin) treatments are used for adjuvant and neoadjuvant treatment of early stages breast cancers.

When generic versions of anthracyclines (like doxorubicin or epirubicin) are available, prices fall dramatically, so for pricing of a new branded anthracycline-based drug (or one not yet generic), we need a reference branded comparator that:

| ▪ | Still                                                  
 holds patent protection or uses a branded formulation, |

| ▪ | Belongs                                                         
 to the same class (anthracycline or anthracy